Alzamend Neuro, Inc. (ALZN) announced on March 16, 2026 that it has begun a Phase II clinical trial of its flagship lithium‑based therapy, AL001, in patients with bipolar disorder type 1. The study, conducted at Massachusetts General Hospital, will compare AL001 to standard lithium carbonate and focus on brain and blood pharmacokinetics.
AL001 employs an ionic cocrystal platform that is designed to deliver higher concentrations of lithium to the brain while limiting systemic exposure. If the trial demonstrates the anticipated safety and efficacy profile, the therapy could eliminate the need for routine therapeutic drug monitoring that is required with conventional lithium carbonate.
Alzamend expects topline data from the Phase II study in the third quarter of 2026. A preliminary imaging study in healthy volunteers is scheduled for release by the end of March 2026, providing early evidence of the drug’s brain‑targeting properties.
The Phase I II study that preceded the current trial established a maximum tolerated dose equivalent to 240 mg of lithium carbonate taken three times daily, a regimen that keeps plasma lithium concentrations below toxic thresholds while maintaining therapeutic exposure.
The company has no product revenue and reported a net loss for the third quarter of 2026. Levered free cash flow over the last twelve months was negative $5.86 million, reflecting the high cash burn associated with clinical development and the typical equity‑financing strategy of a clinical‑stage biopharmaceutical.
CEO Stephan Jackman said, “Our goal with AL001 is to optimize brain lithium delivery while reducing systemic exposure and potentially eliminating the need for burdensome therapeutic drug monitoring.”
Alzamend’s Phase II launch positions the company to advance AL001 toward regulatory milestones and to explore additional neuropsychiatric indications, including major depressive disorder, Alzheimer’s disease, and post‑traumatic stress disorder.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.